Konferenzen zum Thema Onkologie in Großbritannien

Cancer Genomics 2019 is the fourth EACR conference on this topic, and it is now widely recognised as the premier European conference dedicated to cancer genomics. In 2019 it will again cover the latest exciting developments: convergence (modelling, artificial intelligence and big data), single cell analysis of cancers, cancer immune genomics, and clinical applications of genomics.

Email: l.strachan@nottingham.ac.uk

genomics, metastasis, immunology, cancer, oncology, Transcriptome, single cell RNA-seq, epigenetics, genome regulation, bioinformatics, epigenomics, genomics

Dr Vickers introduces the genetic and cellular origins of ovarian and primary peritoneal cancers and explains the science behind a range of targeted treatment approaches. The day will also include the potential of immunotherapy and novel approaches for treatment, screening and patient monitoring.

Conference Team;     Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

The study day will cover the aetiology, prevention and management of cancer treatment to related GI and nutrition issues. The day is for any health care professional with a keen interest in cancer surviorship and more particularly GI and nutritional consequences of cancer treatment within a holistic context.

Conference Team;     Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

The aims of the day are to critically analyse the evidence in relation to the care for older person with cancer in diverse settings, and to critically discuss the implications for clinical practice to ensure a person centred approach for service delivery.

Conference Team;     Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

Krankenpflege und Entbindungspflege,    Geriatrie

Our well respected annual masterclass for clinical nurse specialists and other senior nursing colleagues working in the field of haemato-oncology will take place in Oxford on Sunday 14 July. The course will provide a unique insight into the treatment and management of lymphomas and is a great opportunity to network and share best practice with other haemato-oncology nurse specialists.

Lymphoma Action;     Tel.: [01296619412];     Email: conferences@lymphoma-action.org.uk

lymphoma, CLL, clinical nurse specialist, masterclass, clinical, nurse, specialist, co-morbidities, self management, living with lymphoma, living beyond lymphoma, gilly howard jones, lianne palmer, lymphoma action, rituximab, venetoclax, MURANO trial, haemato-oncology

The sixth annual Lymphoma Management course is returning to Keble College Oxford, Monday 15 - Tuesday 16 July 2019. Our expert faculty of lymphoma specialists from across the UK will provide a comprehensive overview of the diagnosis, treatment and management of lymphomas. This course is aimed at specialist trainees wishing to gain a deeper understanding of lymphoma or consultants who would like to refresh their knowledge. Completion of the course should equip participants in the following areas: 1. The principles underpinning diagnostic and therapeutic modalities as applied to lymphoma in all its subtypes. 2. An understanding of practical considerations when prescribing immunochemotherapy and radiotherapy. 3. To apply the most appropriate diagnostic techniques and therapeutic interventions to individual patients with a lymphoma diagnosis. 4. A thorough training in material which may be covered in professional exams e.g. FRCPath

Lymphoma Action;     Tel.: [01296619412];     Email: conferences@lymphoma-action.org.uk

haematology, haematologist, oncology, oncologist, cancer, lymphoma, blood, lymphatic, lymphocyte, hodgkin, non hodgkin, high grade, low grade, follicular, b cell, t cell, mantle cell, wm, diagnostic, diagnostics, therapeutics, lymsym, symposium, lymphoma action, oxford, churchill, graham collins, toby eyre, charity, bsh, rcpath, cpd, cme

The aim of this study day is to facilitate and equip attendees with the knowledge and skills to care for those with communication and swallowing disorders as a result of their oncological diagnosis or treatments.

Conference Team;     Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

Nanotechnology offers exciting opportunities in the fight against cancer. New technological breakthroughs have enabled innovative therapeutic applications of nanoparticles and have facilitated diagnostics at the nanoscale. As examples, the delivery of RNA with nanoparticles (in the product patisiran), has been approved by EMA/FDA in 2018, while the first liquid biopsy for prostate cancer based on exosome analysis was launched in 2016.

Roger Doxat-Pratt;     Email: roger.doxat-pratt@eacr.org

cancer, nanotechnology, research, oncology, RNA, nanoparticles, nanoscale, therapeutic, treatment, nanomedicine, siRNA, mRNA, CRISPR-Cas9, exosomes, theranostics, immunotherapy

This study day is aimed at dietitians, nurses, doctors and other healthcare professionals working with cancer patients. The world of cancer and nutrition is always changing with on-going research and exploration of this key area. This day will deliver sessions exploring what new evidence has emerged for a variety of cancer diagnosis and how this can be put into practice.

Conference Team;     Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

This one day course is aimed at all healthcare professionals, including nurses, doctors, GP's and pharmacists and any other clinicians caring for patients with a cancer diagnosis

Conference Team;     Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

This year we hope to continue to provide an update on what is new, challenging and controversial in the management of patients with breast cancer. We will address the developing new frontiers of the management of brain metastases in Breast cancer, as well as the role of immunotherapy.

Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

It is great pleasure that we invite you to participate in this very exciting conference on Kidney and Prostate cancer. Both are diverse diseases ranging from small clinically insignificant tumours to advance incurable malignancy.

Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

Urologie, Andrologie,    Nephrologie

Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and Unicancer

MAP 2019 - Molecular Analysis for Personalised Therapy is a unique meeting established by global opinion leaders. The congress aims to integrate insights from tumour sample analysis into daily practice. The MAP Congress has grown into an influential, highly interactive forum which is a natural choice for specialists working in precision medicine in oncology. The Congress programme is based on the genomic information obtained through the sequencing of all tumours and the tumour environment.

Tel.: [+41 91 97 31 947];     Email: meetings@esmo.org

oncology, personalised medicine, precision medicine, genome alterations, genome sequencing, molecular analysis

Pharmakogenomik, Personalisierte Medizin,    Translationale Medizin, Klinische Studien

After the success of the last ten years, it is with great pleasure that you are invited to participate in the eleventh Royal Marsden Head and Neck Conference. The meeting will be of particular interest to maxilliofacial, ENT or plastic surgeons with an interest in head and neck oncology, as well as clinical/medical oncologists, radiologists and pathologists.

Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

Palliative Surgey, pre-frailty and frailty, biology of the ageing cell, end of life care,

This event will provide an overview of cancer immunotherapy, with a focus on the recognition and management of immune-mediated toxicities. The meeting will have a strong clinical emphasis, aimed at providing delegates with practical guidance that can be utilised in daily practice.

Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

The Sixth Royal Marsden lung cancer symposium will tackle burning issues and key challenges facing clinicians treating patients with lung cancer. We have assembled a combination of highly knowledgeable faculty members who will be talking on topics including, lung cancer screening, biomarker testing, systemic and local therapies in both NSCLC and SCLC.

Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

This study day will explore aspects of contemporary haemato-oncology practice delivered by a variety of clinicians working within the specialty.

Conference Team;     Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

The programme will be educational and empowering, covering a wide variety of topics presented by some of the leading experts in their field. The day will consolidate and build on your existing knowledge when caring for this complex group of women.

Conference Team;     Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

The aim of the study day is to facilitate and equip attendees with the knowledge and skills to care for those with communication and swallowing disorders as a result of their oncological diagnosis or treatment.

Conference Team;     Tel.: [02078082921];     Email: conferenceteam@rmh.nhs.uk

Knowing how cells respond to DNA damage is critical to our understanding of tumourigenesis, genomic instability, and the cellular response to DNA-damaging chemotherapy and radiotherapy. DNA damage responses take place in the context of chromatin and in the midst of ongoing transcription and replication. Moreover, the metabolic environment, which is altered in tumour cells, influences these activities. In this conference, we aim to bring together researchers working on understanding DNA damage responses in the context of complex and dynamic cellular environments. This is an exciting and fast moving area, and this conference features an excellent international line-up of speakers. The programme will address the challenges of understanding this complex field and will emphases new experimental approaches for interrogating these pathways. We will also consider how recent advances can be exploited in the clinic.

DNA damage responses, cancer, oncology, Epigenetic, radiotherapy, transcription, immune, repair, tumourigenesis, cellular, genomic